|
Competitor
|
Concentration (nM) causing 50% displacement
|
RBA (%)
|
|---|
|
17,20β-P
|
1.25
|
100.0
|
|
E2
|
37.9
|
4.68
|
|
P4
|
52.6
|
3.37
|
|
17α-OH-P
|
69.3
|
2.56
|
|
11-DOC
|
132.3
|
1.34
|
|
20β-S
|
145.2
|
1.22
|
|
DC
|
207.1
|
0.86
|
|
Flutamide
|
256.1
|
0.49
|
|
o,p'-DDT
|
377.5
|
0.37
|
|
o,p'-DDD
|
549.2
|
0.30
|
|
ZK 112992
|
1179
|
0.11
|
|
ZK 98299
|
12879.8
|
0.01
|
|
F
|
14421.2
|
0.01
|
|
T
|
18347.21
|
0.01
|
|
11-KT
|
ND
|
0.0
|
|
P5
|
ND
|
0.0
|
|
Kepone
|
ND
|
0.0
|
|
Nonylphenol
|
ND
|
0.0
|
|
o,p'-DDE
|
ND
|
0.0
|
|
Cimetidine
|
ND
|
0.0
|
|
ORG 31710
|
ND
|
0.0
|
- ND indicates substances that did not display 50% displacement of 17,20β-P from its receptor in the range of concentrations examined (steroids: 0.1 nM – 10μM, RBA < 0.01%; xenobiotics, hormone antagonists: 0.1 nM – 1 mM, RBA < 0.0001%).
